Showing posts with label Indiana. Show all posts
Showing posts with label Indiana. Show all posts
Thursday, March 6, 2014
Thursday, January 2, 2014
1099 compounding sales jobs in Colorado, Georgia, Iowa, Indiana, Kansas, New Mexico, New Jersey, Minnesota, Missouri, Nevada, New York, Oklahoma, Texas, Washington
1099 Pharmaceutical Representative
NVYDiA Medical - Pharmaceutical Compound SalesIf you are currently in Pharmaceutical or Medical Sales and have established relationships with physicians (Primary Care, Internal Medicine, Neuro's, Ortho's, Plastic's, Podiatrists, Chronic Pain, Spine, Radiation Oncology, Hospice, Urology, Hand Surgeons, Lower/upper Extremity, Sports Medicine, Rheumatology, Rehabilitation, etc.) this is a great opportunity for you.This is not a position you have to leave your current job for. This is an opportunity for you to supplement your income with an additional revenue stream added to your existing salary. This opportunity can increase your yearly income without you going outside of your call pattern, if you have existing relationships. If you have solid contacts in medical, pharmaceutical or other healthcare industries, send your resume and we will contact you.Below is a general description of what you will be offering your physicians:First, we offer everyday used injectable drugs that are administered with in the clinic, for example, B-12, steroid injections, Testosterone injections, antibiotic injections, etc. Our business model has cut out the middle man to offer these products at a discounted price. What makes this sale so easy, is that we are offering products that the doctors or clinics are purchasing, we are just helping them save money.Second, pharmaceutical compounding, (done in compounding pharmacies) is the creation of a particular pharmaceutical product to fit the unique needs of a patient. To do this, compounding pharmacists combine or process appropriate ingredients using various tools. This may be done for medically necessary reasons, such as to change the form of the medication from a solid pill to a liquid, to avoid a non-essential ingredient that the patient is allergic to, or to obtain the exact dose needed. More recently it has been suggested that some doctors and clinics have turned away from major drug manufacturers and turned to compounding pharmacies because they often provide a much higher quality of product and charge much lower prices than the major manufacturers.Positions available in: Colorado, Georgia, Iowa, Indiana, Kansas, New Mexico, New Jersey, Minnesota, Missouri, Nevada, New York, Oklahoma, Texas, WashingtonFor those who meet the qualifications and are interested, send your resume to: resumes@nvydiamedical.com
Thursday, February 21, 2013
Wednesday, February 13, 2013
Indiana Board of Pharmacy Revokes NECC's License
| 2/12/2013 Entry Description
INDIANAPOLIS – The Indiana Board of Pharmacy agreed to revoke the New England Compounding Center’s license for its connection to the meningitis outbreak.
The Massachusetts-based pharmacy reached a voluntary revocation agreement on Friday with Indiana Attorney General Greg Zoeller’s office. The board approved the agreement Monday during its meeting in Indianapolis.
“Public health and safety is a top priority and today’s action was a necessary step to ensure this company, which put patients unnecessarily at risk, does not operate within our state’s borders going forward,” Zoeller said.
Zoeller said a license revocation means the company cannot operate in Indiana for at least seven years. The company could apply for a new license after that time, but the board would have to approve the license application.
In November, the Indiana Board of Pharmacy voted to indefinitely suspend NECC’s non-resident pharmacy license and the Attorney General’s office recently filed a licensing complaint against the company. Zoeller said the pharmacy failed to ensure its epidural steroid injections were safe for patients which led to devastating harm.
As of Feb. 4, the U.S. Centers for Disease Control (CDC) identified 10 deaths and 79 total cases of fungal meningitis in Indiana stemming from epidural steroid injections produced by NECC. Nationwide there were a total of 696 cases and 45 deaths across 20 states.
In September, the CDC in coordination with the Food and Drug Administration identified the NECC as the compounding pharmacy that produced the epidural steroid injections that caused the onset of meningitis in certain patients. Shortly after, NECC ceased production and initiated a recall of the drugs.
As a licensed non-resident pharmacy whose products were distributed and sold in Indiana, NECC is legally responsible for the “proper and safe storage and distribution of drugs and devices.”
-30-
|
| Contact Information: Name: Erin Reece Phone: 317.232.0168 Email: Erin.Reece@atg.in.gov Source found here |
Sunday, January 27, 2013
Indiana Board of Pharmacy Rule Change
Synthetic Drug Emergency Rules
Synthetic Drug Emergency Rules
Indiana Code 25-26-13-4.1 gives the Indiana Board of Pharmacy the authority to adopt emergency rules declaring a substance to be a synthetic drug if the substance has been scheduled or emergency scheduled by the DEA or scheduled, emergency scheduled, or criminalized by another state.
Controlled substances listed in IC 35-48-2-4 are included in Schedule I. “Synthetic drugs,” as defined in IC 35-31.5-2-321, are listed as Schedule I drugs under IC 35-48-2-4(d)(35). Indiana Code 35-31.5-2-321(9) includes in the definition of synthetic drug “any compound determined to be a synthetic drug by rule adopted under IC 25-26-13-4.1.”
The Indiana Board of Pharmacy has promulgated the following emergency rules in accordance with IC 35-26-13-4.1:
LSA #12-493(E)
Indiana Code 25-26-13-4.1 gives the Indiana Board of Pharmacy the authority to adopt emergency rules declaring a substance to be a synthetic drug if the substance has been scheduled or emergency scheduled by the DEA or scheduled, emergency scheduled, or criminalized by another state.
Controlled substances listed in IC 35-48-2-4 are included in Schedule I. “Synthetic drugs,” as defined in IC 35-31.5-2-321, are listed as Schedule I drugs under IC 35-48-2-4(d)(35). Indiana Code 35-31.5-2-321(9) includes in the definition of synthetic drug “any compound determined to be a synthetic drug by rule adopted under IC 25-26-13-4.1.”
The Indiana Board of Pharmacy has promulgated the following emergency rules in accordance with IC 35-26-13-4.1:
LSA #12-493(E)
Thursday, January 17, 2013
Indiana AG files licensing complaint against NECC
INDIANAPOLIS (Legal Newsline) – Indiana Attorney General Greg Zoeller filed a licensing lawsuit Wednesday against the Massachusetts-based pharmacy that is linked to an outbreak of meningitis that killed 37 people across 19 states.
In November, Indiana’s Board of Pharmacy voted to indefinitely suspend the non-resident pharmacy license of the New England Compound Center. The formal licensing complaint will be considered by the board at its February 11 meeting to determine punitive measures.
“This pharmacy failed to ensure its epidural steroid injections were safe for patients which led to devastating harm,” Zoeller said. “This formal licensing complaint against the New England Compounding Center will soon be considered by the Indiana Board of Pharmacy which has the authority to determine the appropriate discipline.”
There were a total of 568 cases and 37 deaths across 19 states as a result of the fungal meningitis stemming from epidural steroid injections produced by NECC. As of Dec. 12, the U.S. Centers for Disease Control and Prevention had identified six deaths and 63 cases in Indiana alone.
In September, the CDC and the U.S. Food and Drug Administration identified NECC as the compounding pharmacy that produced the injections. Subsequently, NECC ceased production of the steroid injections and initiated a recall of the drugs.
As a licensed non-resident pharmacy distributing and selling products in Indiana, NECC is legally responsible for safe and proper storage and distribution of devices and drugs.
Zoeller
“This pharmacy failed to ensure its epidural steroid injections were safe for patients which led to devastating harm,” Zoeller said. “This formal licensing complaint against the New England Compounding Center will soon be considered by the Indiana Board of Pharmacy which has the authority to determine the appropriate discipline.”
There were a total of 568 cases and 37 deaths across 19 states as a result of the fungal meningitis stemming from epidural steroid injections produced by NECC. As of Dec. 12, the U.S. Centers for Disease Control and Prevention had identified six deaths and 63 cases in Indiana alone.
In September, the CDC and the U.S. Food and Drug Administration identified NECC as the compounding pharmacy that produced the injections. Subsequently, NECC ceased production of the steroid injections and initiated a recall of the drugs.
As a licensed non-resident pharmacy distributing and selling products in Indiana, NECC is legally responsible for safe and proper storage and distribution of devices and drugs.
Monday, December 24, 2012
Indiana State Board of Pharmacy Addresses Sterile Compounding Issue
D. Sterile Compounding Discussion (after administrative hearings)
The Board discussed sterile compounding and the recent meningitis outbreak. The Board discussed the fact that not all states inspect pharmacies, as the Board had previously believed. The Board directed the staff to request information from nonresident pharmacies regarding their compounding practices, including their last inspection report and USP 795/797 compliance. This information must be supplied to the Board by December 31, 2012. The Board plans to use this information to help develop an appropriate response to this issue. All nonresident pharmacy applications will be reviewed by the Board, which may delay processing of these applications. The Board discussed the possibility of having a committee regarding this issue. The Board also plans to further investigate third party inspections and accreditation options.
To review complete minutes of the November 5, 2012 meeting click here
Sunday, December 16, 2012
Indiana Board of Pharmacy November Meeting Discussion on Compounding
D. Sterile Compounding Discussion (after administrative hearings)
The Board discussed sterile compounding and the recent meningitis outbreak. The Board discussed the fact that not all states inspect pharmacies, as the Board had previously believed. The Board directed the staff to request information from nonresident pharmacies regarding their compounding practices, including their last inspection report and USP 795/797 compliance. This information must be supplied to the Board by December 31, 2012. The Board plans to use this information to help develop an appropriate response to this issue. All nonresident pharmacy applications will be reviewed by the Board, which may delay processing of these applications. The Board discussed the possibility of having a committee regarding this issue. The Board also plans to further investigate third party inspections and accreditation options.
Minutes of meeting found here
Sunday, December 9, 2012
Indiana Board of Pharmacy to Continue Discussion Regarding Compounding at Next Board Meeting
| ||||||||||||
| ||||||||||||
Saturday, November 17, 2012
Indiana Also Discussed Sterile Compounding During November Meeting and Suspension of NECC
To view the agenda click here and then click on November 2012 agenda.
Indiana Board of Pharmacy Statement regarding compounding pharmacies
October 11, 2012
Indiana Board of Pharmacy
Statement regarding compounding pharmacies
The Indiana Board of Pharmacy takes patient safety very seriously, and the Indiana Code
and our administrative rules are aimed at protecting the public. Compounding is an
integral part of the practice of pharmacy. Compounding is safe when conducted within
the confines of the law and when it does not extend into the realm of manufacturing.
Sterile compounding is addressed at 856 IAC 1-30, and pharmacies engaging in sterile
compounding must comply with the USP 797 national standards. In-state pharmacies,
including those engaging in sterile compounding, are subject to inspection by the Board
of Pharmacy’s Compliance Officers. The Board’s administrative rules and our
inspections of sterile compounding facilities address, among other things: policies and
procedures; engineering controls/physical requirements; personnel training; labeling and
documentation/records and reports; and quality assurance measures. The Board of
Pharmacy works hard to ensure that our licensed facilities are thoroughly inspected.
Non-resident pharmacies registered in Indiana are required by Indiana Code to comply
with the laws and rules of the state in which they are domiciled. In order to be registered
as an Indiana non-resident pharmacy, an applicant must submit numerous documents and
fulfill various duties, including verification of the pharmacy’s licensure in its home state.
The Indiana Board of Pharmacy relies on other state Boards of Pharmacy to regulate
licensees in their jurisdiction.
The Board is following the developments of the meningitis outbreak closely. The New
England Compounding Center is licensed in Indiana as a non-resident pharmacy. The
Board has referred the matter to the Office of the Indiana Attorney General for
investigation.
Patient safety is of utmost importance to the Indiana Board of Pharmacy. The Board of
Pharmacy Compliance Officers thoroughly inspect our licensees with the aim of ensuring
patient safety.
Statement can be found here
Monday, November 5, 2012
Indiana Board of Pharmacy today voted to indefinitely suspend the license of NECC
| ||||||||
|
INDIANAPOLIS
– The
Indiana Board of Pharmacy today voted to indefinitely suspend the license of the
Massachusetts pharmacy connected to the meningitis outbreak.
Indiana
Attorney General Greg Zoeller’s office recently filed an emergency petition
asking the Indiana Board of Pharmacy to suspend the license of the New England
Compounding Center (NECC) which is based in Framingham, Mass. The company
responded last week and agreed to the suspension.
The
board voted 7-0 today on the agreement for indefinite summary suspension during
its scheduled meeting in Indianapolis.
“The
Attorney General’s Office will now move forward with filing a formal complaint
with the Indiana Board of Pharmacy,” Zoeller said. “The board can then consider
the case and determine the most appropriate discipline.”
On Monday, the Indiana State Department of Health (ISDH) confirmed 51 cases of fungal meningitis and four deaths in the state stemming from a tainted steroid injection produced by NECC. As a licensed non-resident pharmacy whose products are distributed and sold in Indiana, NECC is legally responsible for the “proper and safe storage and distribution of drugs and devices.” According to ISDH, there are now 1,502 people in Indiana who have been exposed to the contaminated medication through an epidural or joint injection. Patients exposed in Indiana have been contacted by their healthcare provider. In September, the U.S. Centers for Disease Control and Prevention (CDC) in coordination with the Food and Drug Administration identified the NECC as the compounding pharmacy that produced the epidural steroid injections that caused the onset of meningitis in certain patients. Shortly after, NECC ceased production and initiated a recall of the drugs. As of Nov. 5, the CDC had indentified 404 cases of fungal meningitis and 29 deaths across 19 states stemming from NECC’s tainted steroid injections. The cause of contamination of the steroid injections is still under investigation.
-30-
|
| Contact Information: Name: Erin Reece Phone: 317.232.0168 Email: Erin.Reece@atg.in.gov |
Sunday, October 28, 2012
Indiana knew about meningitis outbreak a week before telling the public, documents show Read more: http://www.foxnews.com/health/2012/10/28/indiana-knew-about-meningitis-outbreak-week-before-telling-public-documents show
Published October 28, 2012
INDIANAPOLIS – State health officials knew six
clinics in Indiana had received a recalled back pain medication linked to an
outbreak of fungal meningitis a week before they notified the public, according
to documents obtained by The Associated Press.
A series of emails obtained Friday through an AP public records request
indicate officials at the Indiana State Department of Health were racing to keep
up with an evolving picture as the disease rapidly spread."A lot of new information was coming in regularly over the weekend of Sept. 29 and 30 from the Centers for Disease Control and Prevention as the situation began to take shape," Amy Reel, a spokeswoman for the state health agency, told The Associated Press.
"This is a fast breaking and fluid situation," Randy Snyder, acute care director for the agency, told other state health officials in an Oct. 3 email.
The emails indicate the CDC informed officials at the Indiana health agency on the night of Sept. 28 it was investigating a cluster of fungal meningitis cases in Tennessee and North Carolina that it suspected were connected with injections of a contaminated steroid. An email attachment identified the six Indiana health facilities that were known to have received the suspected medication from a specialty pharmacy in Massachusetts.
The CDC email urged state health agencies to contact clinics that received the tainted steroid and monitor their patients for signs of meningitis symptoms. The Indiana clinics that received the medication were located in Elkhart, Evansville, Fort Wayne, South Bend, Terre Haute and Columbus.
Snyder told officials in an email Sept. 29 that he had received no reports of meningitis cases. That morning, a Saturday, state epidemiologist Pam Pontones sent an email to CDC intelligence officer Rachel Smith saying, "We'll focus on contacting the facilities on the list first."
"We'll contact the patients," Kristi Williams, pharmacy director at Union Hospital in Terre Haute, told state health officials in an email the following Monday. That same day, Oct. 1, Snyder said in an email that the state health department had contacted by phone and email all six of the health facilities that received the tainted lots of medication. The agency also distributed a "script" for the clinics to read from when notifying patients who may have been exposed.
Reel said Indiana and other states didn't receive data defining how to recognize cases that would be considered part of the outbreak from the CDC until Oct. 2, and the state agency immediately alerted physicians.
"It's critical physicians are made aware of signs and symptoms prior to any public announcement so they can be prepared to discuss those signs and symptoms and appropriately treat patients," Reel said.
As of 6:30 a.m. Oct. 4, health officials weren't aware of any meningitis cases in Indiana, according to the documents. But by shortly after noon, they knew that one case had been confirmed and two more were suspected.
"One case has been identified in Indiana, and we probably have at least two more," Pontones said in an email.
That same day, the state health agency informed the clinics that the state epidemiologist would be contacting them for a list of the patients who had received the tainted injections, and to find out how many patients the clinics had already contacted.
In the same email, Snyder told the clinics that the agency intended to announce the outbreak to the public and planned to identify the facilities that had received the contaminated steroid.
Reel said the state health agencies coordinated the release of information with a CDC press conference on Oct. 4, the same day the first Indiana case was confirmed.
As of Sunday, the CDC meningitis website was reporting 44 cases and three deaths connected with Indiana.
The tainted steroids have been traced to the New England Compounding Center of Framingham, Mass., which has since recalled the contaminated lots and suspended production.
Read more: http://www.foxnews.com/health/2012/10/28/indiana-knew-about-meningitis-outbreak-week-before-telling-public-documents/#ixzz2AdHzvF9j
Saturday, October 27, 2012
Indiana AG targets pharmaceutical company with petition
Posted: 10/27/2012 at 1:15 am
By: Angelle Barbazon
abarbazon@etruth.com
abarbazon@etruth.com
INDIANAPOLIS — Indiana Attorney General Greg Zoeller wants the license of a Massachusetts pharmaceutical company suspended after it was linked to a fungal meningitis outbreak in 18 states.
Zoeller filed an emergency petition today, Oct. 26, asking the Indiana Board of Pharmacy to take a license away from the New England Compounding Center, a drug manufacturer in Framingham, Mass. The company produced contaminated steroid medications used to control back pain. The drugs were recalled Sept. 26 after being distributed to about 75 clinics in 23 states.
Zoeller filed an emergency petition today, Oct. 26, asking the Indiana Board of Pharmacy to take a license away from the New England Compounding Center, a drug manufacturer in Framingham, Mass. The company produced contaminated steroid medications used to control back pain. The drugs were recalled Sept. 26 after being distributed to about 75 clinics in 23 states.
Continue reading here
Saturday, October 20, 2012
Statement from Indiana Board of Pharmacy Regarding New England Compounding Center
October 11, 2012
Indiana Board of Pharmacy Statement regarding compounding pharmacies
The Indiana Board of Pharmacy takes patient safety very seriously, and the Indiana Code and our administrative rules are aimed at protecting the public. Compounding is an integral part of the practice of pharmacy. Compounding is safe when conducted within the confines of the law and when it does not extend into the realm of manufacturing.
Sterile compounding is addressed at 856 IAC 1-30, and pharmacies engaging in sterile compounding must comply with the USP 797 national standards. In-state pharmacies, including those engaging in sterile compounding, are subject to inspection by the Board of Pharmacy’s Compliance Officers. The Board’s administrative rules and our inspections of sterile compounding facilities address, among other things: policies and procedures; engineering controls/physical requirements; personnel training; labeling and documentation/records and reports; and quality assurance measures. The Board of Pharmacy works hard to ensure that our licensed facilities are thoroughly inspected.
Non-resident pharmacies registered in Indiana are required by Indiana Code to comply with the laws and rules of the state in which they are domiciled. In order to be registered as an Indiana non-resident pharmacy, an applicant must submit numerous documents and fulfill various duties, including verification of the pharmacy’s licensure in its home state. The Indiana Board of Pharmacy relies on other state Boards of Pharmacy to regulate licensees in their jurisdiction.
The Board is following the developments of the meningitis outbreak closely. The New England Compounding Center is licensed in Indiana as a non-resident pharmacy. The Board has referred the matter to the Office of the Indiana Attorney General for investigation.
Patient safety is of utmost importance to the Indiana Board of Pharmacy. The Board of Pharmacy Compliance Officers thoroughly inspect our licensees with the aim of ensuring patient safety.
Subscribe to:
Posts (Atom)